Do MAO-B Inhibitors Have Any Role in the Treatment of Depression?
Parkinson’s disease (PD) is clearly associated with changes in affective state and a higher frequency of depression. Depressive symptoms have been found in about 70% of cases of PD , while depression that meets diagnostic criteria and significance is seen in about 40% of PD patients . There is no single type of depression in PD, but rather there are several different depressive syndromes related to the nature of the PD. Mayeux et al.  described depressed PD patients with sleep disturbances, fatigue, psychomotor retardation, and difficulty in concentrating as dominant complaints. Schiffer et al.  reported atypical depression with anxiety and panic disorder to be found significantly more frequently among patients with PD. According to Starkstein et al. , depressed patients with PD reported a significantly higher frequency of worrying, loss of interest, hopelessness, loss of appetite and libido, as well as anxiety, i.e., they showed a predominance of autonomic and affective symptoms. Interestingly, these authors found anergia and motor retardation to be not significantly more frequent in PD patients with depression. In recent years controlled studies have provided evidence that monoamine oxidase inhibitors (MAOIs) are effective antidepressants and comparable to (tricyclic) reuptake inhibitors.
Unable to display preview. Download preview PDF.
- Mayeux R, Stern Y, Williams JBW, Cote L, Frantz A, Dyrenfurth I. Clinical and biochemical features of depression in Parkinson’s disease. Am J Psychiatry 1986; 143: 756–759.Google Scholar
- Schiffer RB, Kurlan R, Rubin A, Boer S. Evidence for atypical depression in Parkinson’s disease. Am J Psychiatry 1988; 145: 1020–1024.Google Scholar
- Laux G, Riederer P, editors. Clinical approaches to moclobemide, a new reversible inhibitor of MAO-A (RIMA). Psychiat Prax Suppl 1990; 17: 1–30.Google Scholar
- Riederer P, Przuntek H, editors. MAO-B-inhibitor selegiline (R-(-)-deprenyl). A new therapeutic concept in the treatment of Parkinson’s disease. J Neural Transm 1987 (Supplement 25): 1–197.Google Scholar
- Overall JE. Efficacy of nomifensine in different depressive syndromes. J Clin Psychiatry 1984; 45 (Sect. 2): 85–88.Google Scholar
- Aylward M, Maddock J, Dewland PM, Lewis PA. Sulpiride in depressive illness. Adv Biol Psychiat 1981; 7: 154–165.Google Scholar
- Zsilla G, Barbaccia ML, Gandolfi O, Knoll J, Costa E. (—)-Deprenyl, a selective MAO-B inhibitor increased 3H-imipramine binding and decreased beta-adrenergic receptor function. Eur J Pharmacol 1983; 11: 117.Google Scholar
- Ceskova E, Svestka J, Nahunek K, Rysanek R, Peska I, Novotna H. Clinical experience with l-deprenyl in endogenous depression. Activ Nerv Sup (Praha) 1986; 28: 47.Google Scholar
- McGrath PJ, Stewart JW, Harrison W, Wager S, Nunes EN, Quitkin FM. A placebo-controlled trial of l-deprenyl in atypical depression. Psychopharmacol Bull 1989; 25: 63–67.Google Scholar
- Sabelli HC. Rapid treatment of depression with selegiline-phenylalanine combination. J Clin Psychiatry 1991; 52: 137.Google Scholar
- Sheehan DV, Davidson J, Manschreck T, Van Wyck Fleet J. Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. J Clin Psychopharmacol 1983; 3: 28–31.Google Scholar